Project Grant R21HL184221
Award Date 8/19/26
Completion Date 6/30/28
Dollars Obligated $118K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Methodist Hospital Research Institute $789,693 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, R01HL172902) to investigate alternative polyadenylation regulation in cardiac fibrosis. The research examines how depletion of the alternative polyadenylation regulator NUDT21 drives three-prime untranslated region shortening of profibrotic transcripts and contributes to...
- The National Heart, Lung, and Blood Institute awarded $249,000 to The University of Texas Southwestern Medical Center on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund investigator-initiated research on fetal congenital heart disease and placental inflammation. Dr. Rachel Leon, an assistant professor in the Division of Neonatal-Perinatal Medicine at UT Southwestern and current NHLBI K23 awardee, will use advanced MRI techniques to investigate the influence...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Ohio State University $772,931 on July 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate membrane-repairing long noncoding RNA MASIR as a therapeutic for ischemic heart injury. The award funds research into a sarcolemma-enriched long noncoding RNA termed MASIR (MG53-associated sarcolemma injury repair lncRNA) that promotes endocytosis and exocytosis to enhance cardiac...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $779,166 on July 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the DELE1 protein in mediating integrated stress response triggered by mitochondrial dysfunction in the heart. The research examines how DELE1 specifically activates the integrated stress response in response to mitochondrial stress—distinct from other cellular stressors—with the goal...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded The University of Texas Southwestern Medical Center $718,548 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endothelial FLI1 in ischemic heart disease. The funded research examines how Friend Leukemia Integration 1 (FLI1), a transcription factor, governs endothelial cell function and protects against myocardial damage under ischemic stress. Preliminary data using...
- The National Heart, Lung, and Blood Institute awarded The University of Chicago $817,976 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop single molecule footprinting methods for studying gene regulation in cardiac differentiation and disease. The recipient will combine methyltransferase-based chromatin measurement with native long-read sequencing to assess chromatin accessibility, nucleosome positioning, transcription factor binding, and DNA...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Southwestern Medical Center $811,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endotrophin in heart failure with preserved ejection fraction. The recipient will conduct basic and translational research examining endotrophin (ETP), a bioactive cleavage product of collagen VI, as a molecular driver of heart failure with preserved ejection fraction...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $795,900 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop gene therapy for FLNC haploinsufficiency cardiomyopathy. FLNC haploinsufficiency, caused by nonsense, frameshift, or splice-site mutations, drives inherited dilated and arrhythmogenic cardiomyopathies characterized by early-onset systolic dysfunction, high malignant arrhythmia risk, and sudden...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...